Drug Profile
Lamivudine/nevirapine/stavudine - Emcure Pharmaceuticals
Alternative Names: Lamivudine/stavudine/nevirapine - Emcure Pharmaceuticals; Nevirapine/lamivudine/stavudine - Emcure Pharmaceuticals; Nevirapine/stavudine/lamivudine - Emcure Pharmaceuticals; Stavudine/lamivudine/nevirapine - Emcure Pharmaceuticals; Stavudine/nevirapine/lamivudine - Emcure PharmaceuticalsLatest Information Update: 21 Nov 2018
Price :
$50
*
At a glance
- Originator Emcure Pharmaceuticals
- Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Nucleosides; Pyridines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 21 Nov 2018 Lamivudine/nevirapine/stavudine is not yet avaliable in USA for HIV-1 infections (Emcure Pharmaceuticals, November 2018)